Business Context and Reporting Period
This Form 8-K Current Report was filed by Anavex Life Sciences Corp. on October 1, 2017. The filing addresses corporate governance and executive compensation matters rather than periodic financial results.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on an executive employment agreement.
Material Changes
Effective October 1, 2017, the Company entered into an Amended and Restated Employment Agreement with Sandra Boenisch, continuing in her capacity as Principal Financial Officer. This agreement replaced the prior contract dated September 17, 2015, which expired on the effective date.
- Compensation: The new agreement establishes a base salary of $120,000 CAD.
- Duties: The agreement clarifies certain duties of the Principal Financial Officer.
- Terms: Aside from the salary and duty clarifications, the terms are materially similar to the original agreement.
Guidance, Outlook, and Risks
The filing contains no guidance, outlook, management commentary on business performance, or discussion of risks and contingencies. The document is limited to the disclosure of the executive compensation arrangement.
Investor Verification Checklist
- Verify the currency conversion rate for the $120,000 CAD salary to determine the USD equivalent.
- Review the referenced Exhibit 10.92 (filed in the 2015 Form 10-K) to compare specific duty clauses between the original and amended agreements.
- Confirm the tenure and performance history of the Principal Financial Officer under the previous agreement.